ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/haematology/lymphoma/other-lymphomas
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Lymphoma / Other lymphomas
27
trial(s) found.
NCT07634289
Radonc
Phase 2
Not yet recruiting
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Phase II
Radio-GLO
Study
bispecific T-cell engager,CD20-targeting
radiotherapy
Diffuse large B-cell lymphoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06876649
Paed
Phase 4
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
BTK inhibitor
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06788509
Advanced
Phase 1
Enrolling by invitation
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring (
PLATFORMPACAN1001
)
BTK inhibitor
Ibrutinib
JNJ-80948543
MALT1 inhibitor
Rezetamig
Safimaltib
bispecific T-cell engager,CD22-targeting
cancer therapy
cancer therapy,BTK-targeting
cancer therapy,CD20-targeting
cancer therapy,CD22-targeting
cancer therapy,CD79b-targeting
cancer therapy,MALT1-targeting
immuno-oncology therapy,CD20-targeting
immuno-oncology therapy,CD22-targeting
immuno-oncology therapy,CD79b-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
trispecific CD79b/CD20/CD3 antibody
Cancer
Castrate-resistant prostate cancer
Leukaemia
Lymphoma
Myelodysplastic syndrome
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
WA
6009 - Nedlands - Linear Clinical Research
NCT06765109
Advanced
Phase 3
Recruiting
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (
ALKAZAR
)
ALK/RET inhibitor
ALK inhibitor,fourth generation
ALK inhibitor,second generation
Lymphoma
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06634589
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (
BGB-16673-104
)
BTK PROTAC degrader
B-cell lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06514794
Paed
Phase 2
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex) (
WUC007-03
)
allogeneic CAR-T-cell therapy,CD7-targeting
Lymphoma
T-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
NCT06414148
Paed
Phase 2
Recruiting
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (
EpLCART
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
immunomodulatory imide drug
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06395103
Paed
Phase 1 / Phase 2
Recruiting
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (
9999-01A
)
anti-ROR1 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
Burkitt lymphoma
Diffuse large B-cell lymphoma
Ewing sarcoma
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT06137144
Paed
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies (
PRIMAVERA
)
PRMT5 inhibitor
PRMT5 inhibitor,MTA-co-operative
Lymphoma
Non-Hodgkin's lymphoma
Peripheral T-cell lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
4575 - Birtinya - Sunshine Coast University Hospital (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (WITHDRAWN)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05991388
Paed
Phase 2 / Phase 3
Recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (
Glo-BNHL
)
Carboplatin
Dexamethasone
Etoposide
Ifosfamide
Loncastuximab Tesirine
Odronextamab
Rituximab
alkylating agent
anti-CD19 antibody-drug conjugate
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
cancer therapy
cancer therapy,CD19-targeting
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD19-targeting
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05947851
Advanced
Phase 3
Recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010) (
1026-010
)
BTK inhibitor
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05607498
Advanced
Phase 1
Recruiting
A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma (
EMB07X101
)
bispecific T-cell engager,ROR1-targeting
Lymphoma
Solid tumour
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - One Clinical Research
NCT05533775
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (
iMATRIX-GLO
)
bispecific T-cell engager,CD20-targeting
Non-Hodgkin's lymphoma
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05279300
Advanced
Phase 1
Recruiting
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination With Systemic Therapies in Patients With Advanced Solid Tumors and Lymphomas (
CS5001-101
)
anti-ROR1 antibody-drug conjugate
Lymphoma
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide (TERMINATED)
NCT04870944
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma (
PEPN2111
)
curaxin,FACT complex-targeting
Cancer
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Lymphoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital (SUSPENDED)
NCT04728893
Advanced
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (
1026-003
)
BTK inhibitor
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Small lymphocytic lymphoma
Waldenström Macroglobulinaemia
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (COMPLETED)
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04094610
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations (
CA127-1029
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Central nervous system cancer
Lymphoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (COMPLETED)
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT03601442
Paed
Available
Managed Access Programs for CTL019, Tisagenlecleucel (
CCTL019B2003I
)
autologous CAR-T-cell therapy,CD19-targeting
Leukaemia
Lymphoma
ACTRN12625001195448
Paed
Phase 1
Recruiting
A Phase I, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of PMCC-COE19 in Patients with CD19-Expressing B-Cell Malignancies (
PLATYPS
)
B-cell lymphoma
Leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
ACTRN12625000965404
Haem
Phase 3
Not yet recruiting
ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation (
CLL-RT2
)
BTK inhibitor
bispecific T-cell engager,CD20-targeting
Cancer
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma,Richter's transformation
ACTRN12625000732482
Haem
Phase 2
Recruiting
CLL12 - An ALLG phase II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (
AETHER-trial
)
Bcl2 inhibitor
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
ACTRN12625000056493
Haem
Phase 1
Not yet recruiting
Microbiome and Fibre Supplementation in Chimeric Antigen Receptor T cell Therapy patients - phase I clinical trial of safety and feasibility of oral fibre supplementation in CAR T (
Micro-Fibre-CAR
)
Leukaemia
Lymphoma
Multiple myeloma
ACTRN12624001142527
Haem
Phase 4
Not yet recruiting
Safety analysis of 90-minute Obinutuzumab infusion in Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL) patients (
nil
)
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Follicular lymphoma
QLD
4870 - Cairns - Cairns Base Hospital
ACTRN12622000308796
Haem
Phase 1
Recruiting
A phase 1 study to assess the safety of short-course treatment with venetoclax prior to non-myeloablative stem cell transplantation for patients with haematological malignancies. (
VICTORY-study
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Leukaemia
Lymphoma
Multiple myeloma
Myelodysplastic syndrome
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
ACTRN12621001361897
Haem
Phase 2
Not yet recruiting
A single arm, open-label study of efficacy and safety of the Exportin 1 inhibitor selinexor in relapsed/refractory CNS Lymphoma and in relapsed/refractory CNS Myeloma (
EXCLAIM
)
XPO1 inhibitor
Diffuse large B-cell lymphoma
Multiple myeloma
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
ACTRN12619000079145
Haem
Phase 1
Not yet recruiting
A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (
The-AutoCAR19-Trial
)
Cyclophosphamide
Fludarabine
Radiotherapy
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
Acute lymphoblastic leukaemia
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6000 - Perth - Royal Perth Hospital
ACTRN12609000116224
Haem
Phase 1 / Phase 2
Not yet recruiting
A pilot study investigating the combination of Mozobil® plus Neulasta® for Hematopoietic progenitor Cell (HPC-A) Mobilization in Patients with Lymphoma or Multiple Myeloma
Filgrastim
Pegfilgrastim
Lymphoma
Multiple myeloma
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (18)
Not yet recruiting (7)
Enrolling by invitation (1)
Recruitment Country and State
VIC (16)
WA (12)
QLD (9)
NSW (9)
SA (5)
NZ (2)
Phase
Phase 1 (7)
Phase 1 / Phase 2 (7)
Phase 2 (6)
Phase 2 / Phase 3 (1)
Phase 3 (3)
Phase 4 (2)
Trial Type
Paed (11)
Haem (8)
Advanced (7)
Radonc (1)
Cancer Therapy Class
CD20
41%
BTK
22%
Bcl2
19%
ROR1
11%
ALK
7%
cereblon
7%
CD19
7%
CD22
4%
CD79b
4%
MALT1
4%
RET
4%
CD7
4%
PD-1
4%
PD-1/PD-L1
4%
PRMT5
4%
IL-6
4%
FACT complex
4%
ROS1
4%
TRK
4%
XPO1
4%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (8)
4101 - South Brisbane - Queensland Children's Hospital (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
3004 - Melbourne, Southbank - Alfred Health (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
2031 - Randwick - Sydney Children's Hospital (3)
6009 - Perth - Perth Children's Hospital (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
5042 - Bedford Park - Flinders Medical Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
6009 - Nedlands - Linear Clinical Research (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
3052 - Parkville - Royal Children's Hospital Melbourne (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
2145 - Westmead - The Children's Hospital at Westmead (2)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (2)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
2217 - Kogarah - St George Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
6009 - Nedlands - One Clinical Research (1)
3002 - East Melbourne - Epworth Freemasons (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4870 - Cairns - Cairns Base Hospital (1)
3066 - Epping - Northern Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
6000 - Perth - Royal Perth Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Lymphoma
Non-Hodgkin's lymphoma
B-cell malignancy
Mature B-cell malignancy
Leukaemia
B-cell lymphoma
Lymphoid leukaemia
Chronic lymphocytic leukaemia
Solid tumour
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Multiple myeloma
Plasma cell disorder
Acute lymphoblastic leukaemia
Neurological cancer
Small lymphocytic lymphoma
Myelodysplastic syndrome
Myeloproliferative neoplasm
Central nervous system cancer
Follicular lymphoma
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Urogenital cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
T-cell acute lymphoblastic leukaemia/lymphoma
B-cell acute lymphoblastic leukaemia/lymphoma
Bone cancer
Burkitt lymphoma
Ewing family of tumours
Ewing sarcoma
Neuroblastic tumour
Neuroblastoma
Peripheral nervous system tumour
Primitive neuroectodermal tumour
Sarcoma
Peripheral T-cell lymphoma
T-cell lymphoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioma
H3K27M-mutant glioma
High-grade glioma
Malignant glioma
Mantle cell lymphoma
Marginal zone lymphoma
Waldenström Macroglobulinaemia
Diffuse large B-cell lymphoma,Richter's transformation
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy